Rowena Sharpe

ALT How is your study leading the way? "We have created the infrastructure to support innovative clinical trials that will improve clinical outcomes for patients of all ages with brain cancer. We hope that the size of this study has the potential to transform brain cancer research in the UK." Professor Colin Watts, Chief Investigator of Tessa Jowell BRAIN MATRIX

ALT How will your trial have a positive impact? "The trial findings are really valuable to non-small cell lung cancer patients previously considered too unwell to tolerate certain treatments. We found evidence that pembrolizumab can be safely administered in a wider group of patients, meaning more can benefit from this drug". Professor Gary Middleton, Chief Investigator of PePS2

ALT Professor Gary Middleton, Chief Investigator of the National Lung Matrix: What makes the trial you run so special? “National Lung Matrix is the first trial of its kind. Its design makes it possible for new drugs and combinations to be added as soon as they become available or retired quickly and easily if evidence suggests they aren’t effective.”

ALT What makes your trial stand out? "CompARE is the first trial in head and neck cancer designed to assess several treatments at the same time. It is one of only a few studies exploring the use of immunotherapy in head and neck cancer. I have very much enjoyed the collaborative nature of the study. There is a real sense of camaraderie." Professor Hisham Mehanna, Chief Investigator of CompARE trial